Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an announcement.
Shareholders in XVIVO Perfusion approved the 2025 accounts and discharged the board and CEO from liability at the annual meeting in Gothenburg, while deciding to retain profits and not distribute a dividend for the year. The decision signals a focus on reinvestment as the company navigates growth and capital needs in the transplant technology sector.
The AGM re-elected most board members, appointed two new directors and confirmed Gösta Johannesson as chair, while KPMG AB was reappointed as auditor and director and committee fees were adjusted. Investors also backed a new long-term, performance-based share option programme for management and key staff and granted the board authority to issue up to 10 percent new shares, moves that strengthen incentives and provide financial flexibility for future expansion.
The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK225.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a Swedish medical technology company specializing in advanced perfusion systems and solutions used to preserve, evaluate and enhance the viability of organs for transplantation. Its products target the global transplant market, aiming to improve clinical outcomes and expand the pool of usable donor organs for healthcare providers worldwide.
YTD Price Performance: 51.34%
Average Trading Volume: 138,555
Technical Sentiment Signal: Buy
Current Market Cap: SEK8.9B
For a thorough assessment of XVIVO stock, go to TipRanks’ Stock Analysis page.